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Abstract
Because of its infrequent and protean presentation and the lack of clinical data, the management of acute infections with the foodborne
trematode Fasciola hepatica is challenging. We report four serologically conﬁrmed cases that illustrate our experience with this parasitic
infection in Chile. All patients were adults presenting with upper abdominal pain. Other symptoms included fever, nausea/vomiting, and
cutaneous manifestations. In all cases, marked eosinophilia was present. All patients lived in an urban environment, and three reported
the consumption of raw watercress. Computed tomography (CT) scans showed hypodense hepatic lesions, whereas ultrasonography
ﬁndings were unremarkable. One patient suffered portal vein thrombosis, which might be a rare complication of acute fascioliasis. All
patients were successfully treated with triclabendazole. Our case series demonstrates that patients with acute fascioliasis typically pres-
ent with a combination of upper abdominal pain, marked eosinophilia, and hypodense hepatic lesions on CT imaging. Diagnosis should
be conﬁrmed by serological investigation. A history of recent consumption of raw watercress is an important ﬁnding, but in some
patients the source of infection remains obscure.
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Introduction
Fascioliasis is a zoonotic disease caused by the foodborne
trematodes Fasciola hepatica and Fasciola gigantica, which usu-
ally infect cattle, sheep, goats, and other domestic ruminants.
Humans are infected after ingestion of larval stages, called
metacercariae, which, after development in lymnaeid inter-
mediate hosts, attach to aquatic and semi-aquatic plants.
Interestingly, the role of humans as solely accidental hosts
has recently been questioned, because, in some regions,
human infection might play a signiﬁcant role in the mainte-
nance of the infectious cycle [1]. Originally a European
disease, F. hepatica fascioliasis has spread to all continents,
and is now the vector-borne disease with the widest geo-
graphical distribution. An estimated 2.4–19 million people
are infected, and 180 million are at risk [2,3]. Hot spots are
the South American highlands, the Nile delta, and the Cas-
pian basin [1]. Owing to its emerging nature and high ende-
micity in some developing countries, the WHO classiﬁed the
disease as a neglected parasitic infection that merits interna-
tional attention. Furthermore, fascioliasis has been recog-
nized as an emerging infection in international travellers and
migrants, causing signiﬁcant diagnostic and therapeutic prob-
lems [4–7].
Other than the larvae of minute liver ﬂukes, which reach the
biliary system ascending through the sphincter of Oddi, Fasciola
larvae cross the intestinal wall, liver capsule and liver tissue on
their way to the biliary tree. During this development, they
cause signiﬁcant tissue damage and, probably frequently, clini-
cal symptoms [8]. However, the acute or hepatic phase of
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fascioliasis is difﬁcult to diagnose, and it mostly occurs in
areas with poor diagnostic possibilities, so it is not surpris-
ing that the clinical features of this infection are poorly
deﬁned. Furthermore, many reports mix acute and chronic
cases of fascioliasis [4,8]. As a result, many physicians and
even infectious diseases specialists outside countries of high
endemicity are not familiar with the presentation and man-
agement of acute fascioliasis [9].
Our report aims to improve the comprehension of acute
fascioliasis by presenting and analysing the clinical and diag-
nostic features of four Chilean patients.
Patients and Methods
Between 2007 and June 2010, four patients with acute fascio-
liasis were diagnosed in the Hospital Militar in Santiago,
Chile, a tertiary-care hospital that receives patients from
Chile’s capital Santiago and also serves as a referral centre
for military personnel and their families from all over Chile.
Detailed patient data were obtained from clinical records,
which were systematically analysed for demographic, epide-
miological and clinical features, as well as laboratory values
and imaging studies. Clinical laboratory values were all
obtained from the hospital’s laboratory. All patients were
examined by abdominal ultrasonography and computed
tomography (CT) scan; the results were revised by an expe-
rienced radiologist using the digital database of the hospital.
Only conﬁrmed cases of acute fascioliasis were included,
deﬁned as patients with the clinical diagnosis of acute fascioli-
asis and positive Fasciola serological ﬁndings. Serological
assays were performed in the Instituto de Salud Pu´blica
(Chilean Institute of Public Health), a national reference cen-
tre for parasitological serology. The following assays were
used: an in-house ELISA with commercial Fasciola antigen
(LMD, Carlsbad, CA, USA); and a commercial immunoblot
(LDBIO Diagnostics, Lyon, France). The former detects anti-
bodies (IgG) against excretory–secretory antigen of F. hepat-
ica; the latter uses whole cell extracts of adult F. hepatica
and serves as a conﬁrmatory assay detecting antibodies (IgG)
against various Fasciola-speciﬁc antigens. Neither test is able
to discriminate acute from chronic infections. All four
patients were positive in both serological assays.
Results
Demographic, epidemiological and clinical variables
Three of our four cases occurred during the spring and sum-
mer months. All patients were residents of urban areas, two
from Santiago de Chile and two from other Chilean cities.
No patient reported rural activities or recent travel. Patients
were middle-aged (mean 46.5 years), and one patient was
female. Three patients reported a history of watercress con-
sumption (Table 1).
All patients presented with upper abdominal pain, one
complained of nausea and vomiting, and two patients had
fever. Two patients suffered from concomitant cutaneous
manifestations (Table 1). Laboratory data demonstrated leu-
kocytosis and severe eosinophilia (absolute eosinophil
count ‡3000/lL). Other markers of inﬂammation, such as C-
reactive protein and sedimentation rate, were only mildly
affected; anaemia was absent. Liver parameters were mostly
unremarkable. None of the patients had hyperbilirubinaemia,
and the values for alkaline phosphatases, glutamate amino-
transferases, c-glutamyltransferase and prothrombin time
were only slightly altered (Table 1).
Before the patients were admitted to our hospital, symp-
toms had been present for an average of 18 days (range 2–
45 days). In all patients, shortly after hospitalization, Fasciola
serological investigation was requested (0–3 days). Antipara-
sitic treatment was started after an average of 10 days
(range 7–12 days). The average duration of hospitalization
was 14 days (range 7–21 days) (Table 1).
Diagnostic studies
The results of imaging studies are summarized in Table 2.
Ultrasound studies were unable to demonstrate focal hepatic
lesions, and therefore did not contribute to the diagnosis of
fascioliasis. In contrast, CT scan imaging demonstrated multi-
ple hypodense hepatic lesions with irregular or diffuse bor-
ders (Figs 1 and 2); track-like or tunnel-like lesions were also
visible. Furthermore, two patients had intra-abdominal lymph
nodes, and one patient had a concomitant portal venous
thrombosis (Fig. 1).
As part of the inclusion criteria, all patients had positive
results in Fasciola ELISA and immunoblot testing. One patient
had an initial undetermined ELISA result, but tested positive
with ELISA and immunoblot 1 month later.
Treatment and follow-up
Before the diagnosis of fascioliasis was made, three
patients received empirical antibiotic treatment for pyo-
genic liver abscesses. All patients were treated with oral
triclabendazole at a dose of 10 mg/kg/day for 1 day (three
patients) or 2 days (one patient). No adverse reactions
were recorded. Three patients were followed up on a
monthly basis for 1–6 months. In all of these patients,
eosinophil counts decreased and clinical symptoms disap-
peared. Recurrence was not reported. Controls for sero-
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logical examinations or parasitological stool examinations
were not performed.
Discussion
Acute fascioliasis refers to the initial, hepatic phase of the
parasitic disease. It is characterized by tissue destruction
caused by the migration of the immature parasites from the
small intestine to the biliary system. Because of its invasive
nature, the acute stage of fascioliasis causes far more mor-
bidity than chronic infection when adult worms inhabit the
biliary tree. However, as for other neglected diseases, com-
prehensive clinical studies are lacking, and the most convinc-
ing clinical data derive from small retrospective case series
or single case reports [4,5,8,10]. The typical clinical spectrum
of acute fascioliasis encompasses anorexia (sometimes associ-
ated with nausea and vomiting), which might lead to weight
loss, abdominal pain, especially in the upper abdomen, tender
hepatomegalia, night sweats, fever, and other immune-
mediated manifestations, such as urticaria or arthralgias.
Other, less frequently reported, ﬁndings include splenomega-
lia, ascites, subcapsular hepatic haematoma, intra-abdominal
haemorrhage, pleural or pericardial effusion, and respiratory
symptoms [2,8,11]. Ectopic larvae in other localizations, such
as subcutaneous tissue, eyes, and the central nervous system,
TABLE 2. Abdominal ultrasonographic and computed tomography (CT) scan ﬁndings in cases of acute fascioliasis
Case 1 Case 2 Case 3 Case 4
Ultrasound Portal vein thrombosis Normal Normal Heterogeneously increased liver density.
Minor dilatation of intrahepatic and
extrahepatic biliary tree
CT scan Several hypodense lesions with
irregular borders in posterior
segment of right lobe, thrombosis
of right portal vein branch,
multiple lymph nodes up to
7 mm in celiac trunk
and major omentum
Conﬂuent hypodense
liver lesions in segments
IV, V, and VIII
Mild hepatomegalia, several hypodense
lesions with irregular borders, tunnel-like
irregular lesions
Hypodense lesions with diffuse limits in
segments VI and VII, dilated bile ducts,
multiple para-aortic and interaorto-caval
lymph nodes up to 1 cm
TABLE 1. Demographic, epidemiological, clinical and laboratory features in cases of acute fascioliasis (at admission)
Case 1 Case 2 Case 3 Case 4
Demographic and epidemiological features
Age (years) 53 56 23 54
Sex Male Male Male Female
Watercress consumption + + + )
Patient background (urban/rural) Urban Urban Urban Urban
Season (year) of disease onset Spring (2007) Summer (2010) Spring (2009) Winter (2007)
Clinical features
Abdominal pain + + + +
Localization of pain Epigastric Right hypochondrium Epigastric Right hypochondrium
Fever + ) + )
Night sweats ) ) + )
Vomiting and nausea ) + ) )
Weight loss ) ) ) )
Cutaneous reactions ) ) Generalized pruritus Facial papular rash, head itch
Clinical timeline
Duration of symptoms before admission (days) 10 14 45 2
Time until fascioliasis was suspected (days)a 1 3 0 3
Time until treatment was started (days)b 9 7 11 12
Duration of hospitalization (days) 21 7 11 17
Laboratory features
Haemoglobin (g/dL) 14 15.4 15.4 13.8
Leukocyte count (cells/lL) 34 200 14 800 14 700 15 300
Eosinophil count (cells/lL) 15 100 9910 4940 6130
Relative eosinophil count (%) 44 67 34 40
Sedimentation rate (mm/h) 30 10 25 13
C-reactive proteinc 7.34 1.5 4.02 0.42
Glutamate aminotransferasec 3.28 1.08 0.54 1.08
Bilirubin (mg/dL) 0.83 0.80 0.74 0.41
Alkaline phosphatasesc 2.35 1.65 2.62 0.84
GGTc 1.47 1.87 2.17
Prothrombin time (INR) 1.78 1.20 1.56 1.07
Serum albumin (g/dL) 4.5 4.2 4.5 4.1
INR, international normalized ratio.
aTime from hospital admission to initiation of Fasciola serological investigation.
bTime from hospital admission to ﬁrst dose of triclabendazole.
cAs ratio to upper normal limit.
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may cause a variety of other clinical manifestations [8]. The
leading laboratory abnormality is hypereosinophilia; hyper-
gammaglobulinaemia and anaemia might also be present [12].
The incubation period ranges from a few days to several
weeks; the acute stage of fascioliasis usually lasts for
2–4 months [2].
The two hallmarks of acute fascioliasis, upper abdominal
pain and marked eosinophilia, were present in all of our four
patients. Other ‘typical’ symptoms, such as fever and cutane-
ous manifestations, were each present in two patients. It is
noteworthy that the skin problems that we recognized were
a papular facial rash with head itch and generalized pruritus,
indicating that the spectrum of dermatological manifestations
of acute fascioliasis might extend beyond the most com-
monly reported symptom, urticaria.
One patient (case 1) was diagnosed with thrombosis of
the portal vein without having risk factors for thrombosis.
To our knowledge, this is the second report of this compli-
cation in association with acute fascioliasis [13]. The throm-
bosis might result from local inﬂammation caused by the
migration of the parasite, or from obstruction by reactive
lymph nodes. Portal venous thrombosis has also been
described in other parasitic infections affecting the liver, such
as cystic and alveolar echinococcosis and chronic schistoso-
miasis [14,15].
In contrast to other highly endemic Andean countries
such as Bolivia and Peru, Chile is a country of low endemic-
ity [16]. In our hospital, only four patients with acute fascioli-
asis were diagnosed during 42 months of observation, with
approximately 50 000 admissions. It is not only its rare
occurrence that makes the diagnosis of this infection a diag-
nostic challenge. The main symptom, upper abdominal pain,
is caused by variety of common diseases, such as gastritis or
biliary diseases. This might be the one reason for the delayed
diagnosis of acute fascioliasis that we and other authors have
recognized [8]. In our patients, the time from symptom
onset to suspicion of fascioliasis (and implementation of Fasci-
ola serology) was 5–45 days (Table 1). Other important
factors in the adequate management of this infection are
the timely availability of serological results and antiparasitic
treatment (triclabendazole). We recognized a time-lapse of
4–11 days between the initiation of serological investigation
and treatment, which contributed to the prolonged hospital
stays. During the time-span until the diagnosis of fascioliasis
was made, most patients received unnecessary antibiotic
treatment for possible pyogenic liver abscess.
Hepatic imaging is crucial in patients with possible acute
fascioliasis. In concordance with other published data [4,8],
abdominal ultrasound did not contribute to the diagnosis of
acute fascioliasis in our four patients (Table 2). However,
this technique is of value in chronic fascioliasis, when adult
worms inhabit the biliary tract, causing inﬂammation and/or
dilatation, and might be seen as mobile structures in the
gall bladder or choledochus [17]. A useful imaging tech-
nique is CT, which reveals hypodense focal lesions that
might be confused with metastasis or abscess; more typical
for acute fascioliasis are hypodense tunnel-like lesions,
which, over time, slowly change in a centripetal manner
[10]. Magnetic resonance imaging, which offers no diagnos-
tic advantage, is characterized by hypointense lesions in T1-
weighted images, and hyperintense signals in T2 images
[12]. Periportal lymph nodes are not infrequent but are
FIG. 1. Computed tomography scan of patient 1, showing several
irregular hypodense focal lesions of the posterior segment of the
right liver lobe (black arrow). The right branch of the portal vein is
blocked by a thrombus (white arrow).
FIG. 2. Computed tomography scan of patient 3, showing multiple
hypodense areas with irregular borders and tunnel-like lesions
(arrows) of the right liver lobe.
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non-speciﬁc. The combination of upper abdominal pain,
marked eosinophilia and hypodense lesion in CT imaging is
highly indicative of acute fascioliasis [12]. Other rare causes
of this combination of ﬁndings include hepatic toxocariasis
and hepatic capillariasis.
Possible or probable cases of acute fascioliasis should be
conﬁrmed by serological tests. As in one of our patients,
serological ﬁndings might be negative or indeterminate in
patients presenting during the early stages, and should be
repeated after 2–3 weeks. Cross-reactions with other helm-
inths, such as Schistosoma sp., small intestinal ﬂukes, and
Toxocara sp., have been described [18,19]. To increase speci-
ﬁcity, a combination of two different immunoassays might be
used. Serum antigen detection is another promising approach
for the diagnosis of acute fascioliasis, including in the early
stages [20]. Coprodiagnostic parasitological studies are
worthless in acute fascioliasis, as this manifestation occurs
during the prepatent period of the infection.
Commonly, fascioliasis is associated with rural environ-
ments and livestock breeding. In Chile and other regions of
low endemicity, however, fascioliasis is not restricted to typi-
cal risk groups, such as children in rural areas [2]. In our
case series, none of the patients lived in a rural setting, but
most patients (three of four) reported recent consumption
of raw watercress (‘berros’). Interestingly, reports from
France indicate that commercially cultivated aquatic plants
also pose a Fasciola risk [21]. In some endemic countries,
seasonality of Fasciola infection has been observed [22,23].
Three of our four patients presented during the Chilean
spring and summer months. Reasons for this probable sea-
sonality might be climatic factors that inﬂuence the popula-
tions of intermediate snail hosts, and the higher availability
and consumption of vegetables during these seasons.
Triclabendazole is the drug of choice for this parasitosis.
It is active against mature and immature forms of the para-
site. Treatment consists of a single oral dose of 10 mg/kg; in
cases of failure, triclabendazole treatment is repeated at a
higher dosage of 20 mg/kg (in two doses separated by 12–
24 h) [2]. The drug is effective and has an excellent safety
proﬁle [24,25]. Adverse reactions are usually mild, and
include abdominal pain and, less frequently, vomiting or nau-
sea, cough, urticaria, and pruritus [2,25,26]. Criteria of cure
of acute fascioliasis are alleviation of clinical symptoms
(sometimes a temporary exacerbation might be observed),
normalization of eosinophilia, and a decrease in Fasciola-spe-
ciﬁc antibodies or circulating antigen [2]. Stool examinations
for ova and parasites might be applied several weeks after
therapy to demonstrate eradication of the parasite. None-
theless, neither for diagnosis nor follow-up is a standardized
protocol available [2]. In all of our patients, triclabendazole
was successfully administered, and no adverse effects or
recurrence were reported.
Although limited by its low number and retrospective
design, our case series demonstrates that, despite the non-
speciﬁc and elusive nature of acute fascioliasis, patients typi-
cally present with a combination of abdominal pain, marked
eosinophilia, and hypodense hepatic lesions on CT imaging.
A history of recent consumption of raw watercress or other
aquatic plants is normally but not always present. The diag-
nosis should be conﬁrmed by serological investigation,
although, in very early stages, repeated testing might be nec-
essary. Unfamiliarity of physicians with the disease and delays
in the availability of serological results and antiparasitic
medication might contribute to prolonged hospitalization.
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